Clinical trial NCT03045861: Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
Official title: A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Infection, Human Immunodeficiency Virus
HIV Infections
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2017-02-08
Enrollment: 33
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the treatment of HIV-1 infection in combination with other antiretroviral therapy (ART). This study will be a 10-day monotherapy, open-label, adaptive, dose ranging, repeat-dose study. This study will be conducted in two Parts (Part A and Part B) consisting single daily doses of GSK2838232 and Cobicistat from Day 1 to Day 10. This proof of concept open-label study will be aimed to characterize the acute antiviral activity, pharmacokinetics (PK), the relationship between PK and antiviral activity, and safety of GSK2838232/cobi administered across a range of doses over 10 days in HIV-1 infected patients. A cohort of 10 subjects will be studied in Part I followed by interim (go/no-go) analysis of Part A data. On completion of an interim analysis of part A data, further cohorts of 8 subjects will then be studied in Part B in a parallel design in two or more cohorts (depending upon the data obtained in Part A). Approximately 34 HIV-1 infected treatment-naive subjects will be enrolled during the study. Subjects in both parts will have a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose. Maximum duration of study participation will be approximately 6 Weeks.


Eligibility criteria: Inclusion Criteria:

* Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
* Healthy (other than HIV infection) male or female as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring, defined as no other chronic medical conditions and taking no chronic medications.
* A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the medical monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
* A creatinine clearance \>80 mL/minute as determined by Cockcroft-Gault equation creatinine clearance CLcr (mL/minute) = (140 - age) x weight (Wt) divided by (72 x serum creatinine \[Scr\]) (times 0.85 if female) where age is in years, Wt is in kilogram (kg), and Scr is in units of mg/decilitre (dL).
* Confirmed HIV positive; CD4+ cell count \>=350 cells/millimetre (mm)\^3 and plasma HIV-1 RNA \>=5000 copies/mL at screening.
* No current and no prior ART.
* Body weight \>=50 kg (110 pound \[lbs.\]) for men and \>=45 kg (99 lbs) for women and body mass index (BMI) within the range 18.5-31.0 kg/meter\^2 (inclusive)
* A female subject of reproductive or non-reproductive potential is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin (hCG) test at screening and prior to first dose), not lactating, and at least one of the following conditions applies: females of reproductive potential may only be enrolled if they are using two forms of complementary contraception, which must include one barrier method. They will be counselled on safer sex practices; there is no definitive drug-drug interaction (DDI) information with GSK2838232 and an interaction with oral contraceptives is possible, so other (barrier, inter-uterine device etc.) methods of contraception will be required; fertile females, who have an established, long-term lifestyle of sexual abstinence, or only same sex partners, require no other means of birth control. Pre-menopausal females with one of the following: documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; documented bilateral oophorectomy; postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
* Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until one week after the last dose of study medication; vasectomy with documentation of azoospermia; male condom plus partner use of one of the contraceptive options as: Contraceptive sub dermal implant including a \<1 percent rate of failure per year; intrauterine device or intrauterine system including a \<1 percent rate of failure per year; oral contraceptive, either combined or progestogen alone or injectable progestogen; contraceptive vaginal ring; percutaneous contraceptive patches. These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
* Capable of giving signed informed consent.

Exclusion Criteria:

* Alanine aminotransferase (ALT) and bilirubin (BIL) \>1.5 x upper limit of normal (ULN), isolated BIL \>1.5xULN is acceptable if BIL is fractionated and direct BIL \<35 percent.
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); hepatitis B virus (HBV) and/or hepatitis C virus (HCV) positive.
* Subjects who have any other chronic medical condition, including cardiovascular (CV), respiratory, neurologic, psychiatric, renal, gastrointestinal (GI), oncologic, rheumatologic, or dermatologic.
* Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.
* Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety.
* History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of \>14 drinks for males or \>7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
* Smoking is an exclusion criteria for this study. Subject having urinary cotinine levels indicative of smoking at screening.
* Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion criteria.
* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
* Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
* Screening or Baseline cardiac troponin I greater than the 99 percent cutoff (\>0.045 nanogram \[ng\]/mL by the Dimension Vista cardiac troponin \[CTN\] I assay).
* A positive pre-study drug/alcohol screen.
* Prior history of receiving an HIV maturation inhibitor
* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
* Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 30 days of study drug administration or anticipated need for such treatment within the study.
* Treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity (such as hydroxyurea or foscarnet) within 30 days of study drug administration.
* An active Center for Disease Control and Prevention (CDC) category C disease except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial.
* Treatment with any vaccine within 30 days prior to receiving study medication.
* Exclusion criteria for 24-hour screening holter: any symptomatic arrhythmia (except isolated extra systoles); sustained cardiac arrhythmias (such as atrial fibrillation, flutter or supraventricular tachycardia \[\>=10 seconds\]); non-sustained or sustained ventricular tachycardia (defined as \>=3 consecutive ventricular ectopic beats); any conduction abnormality including but not specific to left or complete bundle branch block, atrioventricular (AV) block, high grade or complete heart block Wolff-Parkinson-White (WPW) syndrome etc.; sinus pauses \>3 seconds.
* Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): heart rate \<45 and \>100 beats per minute (bpm) for males, and \<50 and \>100 bpm for females; PR Interval \<120 and \>220 milliseconds (msec); QRS duration \<70 and \>120 msec; corrected QT (QTc) interval \>450 msec; Evidence of previous myocardial infarction (Does not include ST segment changes associated with repolarization); any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block \[2nd degree or higher\], WPW syndrome); sinus pauses \>3 seconds; any significant arrhythmia which, in the opinion of the principal investigator or GSK medical monitor, will interfere with the safety for the individual subject; non-sustained or sustained ventricular tachycardia (\>=3 consecutive ventricular ectopic beats).

Primary outcomes:
measure: Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)
timeFrame: Baseline (Day 1) to Day 21
measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Up to Day 22
measure: Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance
timeFrame: Up to Day 22
measure: Number of Participants With Hematology Parameter Abnormalities of Potential Clinical Importance
timeFrame: Up to Day 22
measure: Number of Participants With Liver Function Laboratory Abnormalities of Potential Clinical Importance
timeFrame: Up to Day 22
measure: Number of Participants With Abnormal Urine Parameters
timeFrame: Up to Day 22
measure: Number of Participants With Abnormal Electrocardiogram (ECG) Findings
timeFrame: Up to Day 22
measure: Number of Participants With Vital Signs Data Outside Clinical Concern Range
timeFrame: Day 1 (pre-dose)
measure: Number of Participants Who Were Administered Concomitant Medications
timeFrame: Up to Day 22
measure: Area Under the Plasma Concentration Time Curve From Zero (Pre-dose) to 24 Hours (AUC[0 to 24]) for GSK2838232 on Day 1
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1
measure: Maximum Observed Concentration (Cmax) for GSK2838232 on Day 1
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1
measure: Time to Maximum Observed Concentration (Tmax) for GSK2838232 on Day 1
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1
measure: Absorption Lag Time (Tlag) for GSK2838232 on Day 1
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1
measure: Concentration of GSK2838232 at 24 Hours Post-dose on Day 1
timeFrame: 24 hours post-dose on Day 1
measure: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0 to Tau]) for GSK2838232 on Day 10
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10
measure: Pre-dose Concentration (C0) of GSK2838232 on Day 10
timeFrame: Pre dose on Day 10
measure: Concentration at End of Dosing Interval (Ctau) for GSK2838232 on Day 10
timeFrame: 24 hours post-dose on Day 10
measure: Cmax for GSK2838232 on Day 10
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10
measure: Apparent Oral Clearance of GSK2838232 Following Administration on Day 10
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10
measure: Terminal Elimination Half-life (T1/2) of GSK2838232 Following Administration on Day 10
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10
measure: Tmax for GSK2838232 Following Administration on Day 10
timeFrame: Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10
Secondary outcomes:
measure: Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 AUC (0 to Tau)
timeFrame: Baseline (Day 1), Days 10 and 11
measure: Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Cmax
timeFrame: Baseline (Day 1), Days 10 and 11
measure: Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Ctau
timeFrame: Baseline (Day 1), Days 10 and 11
measure: Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count to Day 11
timeFrame: Baseline (Day 1) and Day 11
measure: Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 AUC (0 to Tau)
timeFrame: Baseline (Day 1), Days 10 and 11
measure: Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Cmax
timeFrame: Baseline (Day 1), Days 10 and 11
measure: Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Ctau
timeFrame: Baseline (Day 1), Days 10 and 11
measure: Number of Participants With Emergent Drug Resistance Mutations
timeFrame: Up to Day 11
measure: Accumulation Ratio for GSK2838232
timeFrame: pre dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Days 1 and 10; pre-dose on Days 3, 4, 5, 8 and 9; Days 12 and 14
measure: Dose Proportionality of GSK2838232
timeFrame: pre dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Days 1 and 10
measure: Pre-morning Dose Concentrations (C0) on Day 2 Through 11
timeFrame: Pre-dose on Days 2, 3, 4, 5, 8, 9, 10 and 11
measure: Steady State Assessment of Plasma Pre-dose Concentrations by Treatment
timeFrame: Pre-dose on Days 8, 9 and 10
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: GSK Investigational Site
state: Alabama
city: Bakersfield
country: United States
facility: GSK Investigational Site
state: California
city: Los Angeles
country: United States
facility: GSK Investigational Site
state: California
city: Los Angeles
country: United States
facility: GSK Investigational Site
state: California
city: Fort Pierce
country: United States
facility: GSK Investigational Site
state: Florida
city: Miami
country: United States
facility: GSK Investigational Site
state: Florida
city: Orlando
country: United States
facility: GSK Investigational Site
state: Florida
city: Springfield
country: United States
facility: GSK Investigational Site
state: Massachusetts
city: Berkley
country: United States
facility: GSK Investigational Site
state: Michigan
city: Newark
country: United States
facility: GSK Investigational Site
state: New Jersey
city: Dallas
country: United States
facility: GSK Investigational Site
state: Texas
city: Longview
country: United States
facility: GSK Investigational Site
state: Texas
city: Toronto
country: Canada
facility: GSK Investigational Site
state: Ontario
city: Montreal
country: Canada
facility: GSK Investigational Site
state: Quebec
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico CL, Jeffrey J, Gan J, Xu J, Felizarta F, Scribner A, Ramgopal M, Benson P, Johns BA. A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis. 2020 Aug 22;71(5):1255-1262. doi: 10.1093/cid/ciz938.